Emberley, E., Pan, A., Chen, J., Dang, R., Gross, M., Huang, T., . . . Parlati, F. (2021). The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma. Public Library of Science (PLoS).
Style de citation Chicago (17e éd.)Emberley, Ethan, et al. The Glutaminase Inhibitor Telaglenastat Enhances the Antitumor Activity of Signal Transduction Inhibitors Everolimus and Cabozantinib in Models of Renal Cell Carcinoma. Public Library of Science (PLoS), 2021.
Style de citation MLA (8e éd.)Emberley, Ethan, et al. The Glutaminase Inhibitor Telaglenastat Enhances the Antitumor Activity of Signal Transduction Inhibitors Everolimus and Cabozantinib in Models of Renal Cell Carcinoma. Public Library of Science (PLoS), 2021.